BridgeBio Pharma 2026年季度报告

FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter)________________________________________________________ Name of each exchange on which registered Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) hasbeen subject to such filing requirements for the past 90 days.YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit such files).YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”and “emerging growth company” in Rule 12b-2 of the Exchange Act.________________________________________________________ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the ExchangeAct).YesNo As of August3, 2026, the registrant had 195,487,474 shares of common stock, $0.001 par value per share, outstanding. Special Note Regarding Forward‑Looking Statements This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of theSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Many of these statementscan be identified by the use of terminology such as “believes,” “expects,” “intends,” “anticipates,” “plans,” “may,” “will,” “could,”“would,” “projects,” “continues,” “estimates,” “potential,” “opportunity” or the negative versions of these terms and other similarexpressions. The forward-looking statements in this Quarterly Report on Form 10-Q include, but are not limited to, statementsregarding: •the continued commercial success of Attruby(acoramidis), including our expectations regarding the size and growthpotential of the commercial markets for Attruby;•the success, cost and timing of our clinical development of our late-stage product candidates, including low-doseinfigratinib for achondroplasia, encaleret for ADH1, and BBP-418 for limb-girdle muscular dystrophy type 2I/R9, orLGMD2I/R9;•our ability to continue planned preclinical and clinical development of our respective development programs, and thetiming, cost and success of any such continued preclinical and clinical development and planned regulatory submissions;•our ability to initiate, recruit and enroll patients in and conduct our clinical trials at the pace that we project;•the expected timing of our regulatory submissions, and our anticipated interaction with and feedback from the U.S. Foodand Drug Administration (the “FDA”) and similar regulatory authorities;•our plans to implement certain development strategies, including our ability to attract and retain potential collaboratorswith development, regulatory and commercialization expertise;•our ability to obtain and maintain regulatory approval of our product candidates in any of the indications for which weare developing or we plan to develop, and any related restrictions, limitations or warnings in the label of any of ourproduct candidates, if approved;•our ability to successfully commercialize our current product candidates, if approved, and any other product candidateswe may identify and pursue, if approved, including our ability to successfully build a specialty sales force andcommercial infrastructure to market our current product candidates and any other product candidates we may identifyand pursue;•our ability to compete with companies currently marketing approved treatments or engaged in the development oftreatments that may become available for any of the indications that our product candidates are designed to target;•our reliance on third parties to conduct our clinical trials and to manufacture drug substance and drug product for ourcommercial product and certain of our product candidates for use in our clinical trials;•our ability to contract with and the performance of our and our collaborators’ third-party suppliers and manufacturers;•the pricing and reimbursement of our product candidates, if approved;